$995 | Single User
$1990 | Site License
$2495 | Global License

Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin
[Feb 2016]
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2016 | 305 | In Stock
Related Topics: GlaxoSmithKline , Novartis

Introduction

Introduction


This edition presents key opinion leader (KOL) views on recent developments in the chronic obstructive pulmonary disease (COPD) market. Topics covered include the clinical role of MABAs (muscarinic antagonists/beta2 agonists), with GlaxoSmithKline recently initiating Phase II trails with batefenterol, including a combination study with an ICS (fluticasone furoate). KOL’s views of asthma COPD overlap syndrome (ACOS) are explored, including the prospects for GSK’s ICS/LAMA combination that was tested specifically in patients with ACOS. Novartis is developing a “smart” Breezhaler/Neohaler device that electronically captures adherence data: KOLs assess how this novel feature might improve adherence.


Key Questions Answered in this Update Bulletin:


  • What is the role of MABAs (muscarinic antagonists/beta2 agonists) and what advantages do they offer over current bronchodilators?

  • What is the rationale for developing MABA/ICS combinations?

  • Will MABA/ICS provide similar benefits to the more clinically advanced LAMA/LABA/ICS combinations?

  • Could a MABA be combined with an ICS and an additional anti-inflammatory agent?

  • Will asthma COPD overlap syndrome (ACOS) be recognized by physicians or regulators as a distinct clinical entity?

  • Could Novartis’s novel ‘Smart’ Breezhaler/Neohaler device improve adherence?

  • Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

    Table of Contents
    for Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016] [Published by FirstWord Pharma]

    • -

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    305 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    Global Chronic Kidney Disease Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    The Outlook for Wearable Health Tech in Managing Chronic Disease
    IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
    01 May 2016 by FirstWord Pharma USD $695 More Info
    Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]
    IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
    01 Feb 2016 by FirstWord Pharma USD $995 More Info
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015SummaryGlobalD...
    30 Oct 2015 by Global Data USD $2,500 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
    01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
    Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
    IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
    20 Apr 2015 by FirstWord Pharma USD $7,900 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
    27 May 2014 by FirstWord Pharma USD $7,900 More Info
    Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
    IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
    20 Jan 2014 by FirstWord Pharma USD $7,495 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016] [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...